ライフサイエンスコーパス: hydrocortisone

1 of a physiological dose of 4 mg of cortisol (hydrocortisone).

2 y (ie, methotrexate with both cytarabine and hydrocortisone).

3 icoids; this T-cell response was hindered by hydrocortisone.

4 Performance on the CVLT was not affected by hydrocortisone.

5 ls in the presence of cytokines, stroma, and hydrocortisone.

6 inephrine > or = 1,25-(OH)(2) vitamin D(3) > hydrocortisone.

7 tients with adrenal failure not treated with hydrocortisone.

8 d is suppressed by topical administration of hydrocortisone.

9 continued within 24 hrs of the first dose of hydrocortisone.

10 amin plus hydrocortisone versus placebo plus hydrocortisone.

11 mbined androgen deprivation and suramin plus hydrocortisone.

12 loxacin plus dexamethasone) or neomycin plus hydrocortisone.

13 enous adrenal function was not suppressed by hydrocortisone.

14 as the LPR was abolished by cromoglycate and hydrocortisone.

15 ich parallels that of MNCs after intravenous hydrocortisone.

16 weeks indefinitely; and replacement doses of hydrocortisone.

17 atment with either 5-iodo-2'-deoxyuridine or hydrocortisone.

18 amcinolone > dexamethasone > betamethasone > hydrocortisone.

19 out IL-1 3 prior to stimulation with LPS and hydrocortisone.

20 o two groups, based on the administration of hydrocortisone.

21 C) in high-risk patients can be reduced with hydrocortisone.

22 ortisone + placebo, or 4) triiodothyronine + hydrocortisone.

23 in the total brain volume was observed with hydrocortisone.

24 blocked the volume reduction associated with hydrocortisone.

25 ation before and 24 hours after the start of hydrocortisone.

26 were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, foll

27 Hydrocortisone (0.6 mg/mice i.p.) was administered immed

28 ceive clobetasol propionate, 0.05% cream, or hydrocortisone, 1%, cream.

29 Hydrocortisone (10(-9) M) had no effect on NHE3 activity

30 All patients were administered hydrocortisone (100 mg every 8 hrs) for the first 24 hrs

31 ore, and after, the intravenous injection of hydrocortisone (100 mg) at 1, 2, 4, 8, and 24 hrs.

32 In another study, hydrocortisone (100 mg) was given 2 hours before the stu

33 erioperative high-dose corticosteroids (HDS; hydrocortisone, 100 mg, intravenously 3 times daily, fol

34 Oral hydrocortisone, 13 mg/m2 of body surface area every morn

35 Participants received hydrocortisone (160 mg/day)/placebo, phenytoin/placebo,

36 ohn's disease were randomized to intravenous hydrocortisone 200 mg or placebo immediately before thei

37 d, double-blind, placebo-controlled trial of hydrocortisone (200 mg/d for 7 d) in patients with sever

38 re a memory encoding task; 2) received 10 mg hydrocortisone 210 minutes (slow cortisol) before a memo

39 ed to one of three groups: 1) received 10 mg hydrocortisone 30 minutes (rapid cortisol effects) befor

40 gether with K (400 mg orally [p.o.] tid) and hydrocortisone (30 mg p.o. each morning, 10 mg p.o. each

41 r resuscitation was treated with stress-dose hydrocortisone (300 mg daily for 7 days maximum and grad

42 A dose of hydrocortisone (4 microg/kg/min for 6 hrs) that maintain

43 received consecutive treatment with low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month and pla

44 fusion titrated up to 0.06 U/min and then IV hydrocortisone (50 mg 6 hourly) or placebo.

45 amin plus hydrocortisone versus placebo plus hydrocortisone, a posttherapy decline in PSA of > or = 5

46 WT), severe combined immunodeficient (SCID), hydrocortisone acetate (HC)-treated WT, and HC-treated S

47 on.The aim of this study was to confirm that hydrocortisone acetate (HC-ac) ophthalmic ointments of 2

48 r efficacy than a control group treated with Hydrocortisone acetate 0.5% therapy.

49 Hydrocortisone acetate 2.5% and Hydrocortisone acetate 1% eye ointments are efficacious

50 Hydrocortisone acetate 2.5% and Hydrocortisone acetate 1

51 In the absence of hydrocortisone, acid incubation increased NHE3 protein a

52 bundance by 47%; in the presence of 10(-9) M hydrocortisone, acid incubation increased NHE3 protein a

53 These data indicate that hydrocortisone acts directly on BCBL-1 cells to activate

54 2 weeks after test dosing, and also received hydrocortisone, acyclovir, and Bactrim or equivalent pro

55 n were reduced in a dose-dependent manner by hydrocortisone added to cocultures.

56 ptic shock do not benefit from moderate-dose hydrocortisone administered to overcome etomidate-relate

57 There are few reports on hydrocortisone administration after cardiac arrest, and

58 e of infection, a protective effect of early hydrocortisone administration against unfavorable outcom

59 he results demonstrate a correlation between hydrocortisone administration and the high rates of surv

60 This study aimed to evaluate the effect of hydrocortisone administration on the outcomes of patient

61 The high-dose hydrocortisone administration reduced the percent of spe

62 f mitoxantrone and hydrocortisone (M+H) over hydrocortisone alone with respect to survival duration.

63 vival (12.3 months for M+H v 12.6 months for hydrocortisone alone).

64 and disease progression in favor of M+H over hydrocortisone alone, there was no difference in overall

65 trial of suramin plus hydrocortisone versus hydrocortisone alone.

66 fit of M+H with respect to pain control over hydrocortisone alone.

67 ailure and disease progression compared with hydrocortisone alone.

68 RPC were randomized to receive either M+H or hydrocortisone alone.

69 Hydrocortisone also led to diminished production of indu

70 one patients were allocated to vasopressin + hydrocortisone and 30 patients to vasopressin + placebo.

71 Suramin plus hydrocortisone and androgen deprivation has limited appl

72 the score fell by 7.2 points for patients on hydrocortisone and by 3.3 points for those on placebo (p

73 less sensitive to the inhibitory effects of hydrocortisone and dexamethasone on allergen-induced pro

74 ssigned to DAA alone (24 mug/kg/h for 96 h), hydrocortisone and fludrocortisone alone, their respecti

75 Hydrocortisone and high-dose aspirin prevented endotheli

76 the steroid antagonist mifepristone, whereas hydrocortisone and other steroids mimicked the effects o

77 acute antidepressant effects of intravenous hydrocortisone and ovine corticotropin releasing hormone

78 ed the effect of exogenous administration of hydrocortisone and partially prevented the detrimental e

79 pocampus revealed no differences between the hydrocortisone and placebo conditions; however, post-cha

80 ficant differences were observed between the hydrocortisone and placebo groups for time until septic

81 Adding hydrocortisone and stromal cells greatly increases the f

82 both activation of the virus by the steroid hydrocortisone and the large number and variation in enh

83 These therapies include hydrocortisone and vasopressin.

84 neural level, the combined administration of hydrocortisone and yohimbine reduced the sensitivity of

85 rmed that the simultaneous administration of hydrocortisone and yohimbine renders instrumental behavi

86 ated in habit learning were not modulated by hydrocortisone and yohimbine.

87 ted by HG or high hydrocortisone (HC: 500 nM hydrocortisone) and was lower in heavier animals.

88 4 (95% CI, 1.32-2.85) for ciprofloxacin plus hydrocortisone, and 2.00 (95% CI, 1.18-3.41) for ciprofl

89 y (simultaneously administered methotrexate, hydrocortisone, and cytarabine) for 165 consecutive chil

90 ontact with stromal ligands, human serum, no hydrocortisone, and IL-2), significant numbers of CD56+/

91 nized the effects of the GCs corticosterone, hydrocortisone, and prednisolone, but not the synthetic

92 cts of pharmacotherapies (eg, beta blockers, hydrocortisone, and selective serotonin re-uptake inhibi

93 line) were grown to confluence, primed with hydrocortisone, and then exposed to the PRLs.

94 recommends the use of docetaxel, prednisone/hydrocortisone, and/or mitoxantrone in specific settings

95 eneration by PMNLs and MNCs was inhibited by hydrocortisone at 1 hr; this effect peaked at 2 hrs and

96 eceive a 42-hr continuous infusion of either hydrocortisone at 200 mg/day (HC group; n = 49) or salin

97 Specifically, administration of hydrocortisone at doses analogous to those achieved unde

98 acute tympanostomy-tube otorrhea to receive hydrocortisone-bacitracin-colistin eardrops (76 children

99 bine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy

100 compared with immature enterocytes and that hydrocortisone can accelerate this maturational process.

101 decrease in CT-clathrin colocalization in H4/hydrocortisone compared with H4 cells by electron micros

102 th severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the

103 h" conditions (contact with stromal ligands, hydrocortisone-containing long-term culture medium, IL-2

104 randomized to receive either high-dose oral hydrocortisone (cortisol) acetate (4-6 mg/kg/d) or place

105 Hydrocortisone could transiently correct hypoglycemia in

106 or three small solutes-water, L-glucose, and hydrocortisone-covering a wide range of membrane permeab

107 Hydrocortisone decreased hyaluronan levels approximately

108 study in patients with trauma, we found that hydrocortisone decreased the blood level of interleukin-

109 Patients treated with hydrocortisone demonstrated a significantly greater redu

110 ylation and CD23 expression in monocytes and hydrocortisone-dependent IgE switching in B cells.

111 cids only in the high insulin group, however hydrocortisone did not affect the levels of acyl carniti

112 ithout adrenal insufficiency, treatment with hydrocortisone did not affect vasopressor dose at 24 hrs

113 esults show that testosterone, estrogen, and hydrocortisone did not alter basal CatSper currents, whe

114 y increased plasminogen mRNA expression, but hydrocortisone did not markedly enhance the response to

115 However, 10(-9) M hydrocortisone did not modify the effect of acid incubat

116 n the absence of protein synthesis, 10(-9) M hydrocortisone did potentiate an effect of acid on NHE3

117 Of patients who survived to have their hydrocortisone dose changed, 57% had their corticosteroi

118 Hydrocortisone dose-dependently inhibited LPS-induced IL

119 the group that received the 4 microg/kg/min hydrocortisone dose.

120 sepsis, a 5- to 7-day course of physiologic hydrocortisone doses with subsequent tapering increases

121 randomized to receive one of three different hydrocortisone doses, by intravenous infusion, for 6 hrs

122 foration between quinolone and neomycin plus hydrocortisone ear drop-exposed children.

123 , adrenal insufficiency must be treated with hydrocortisone early in life.

124 r-alpha was lower among patients who had had hydrocortisone early.

125 progesterone equivalent (PEQ) and 13.5 ng/l hydrocortisone equivalent (HEQ).

126 00 mg (range, 50-267 mg of hydrocortisone or hydrocortisone equivalent for dexamethasone); the median

127 85 mg (range, 50-890 mg of hydrocortisone or hydrocortisone equivalent for prednisone).

128 r low-dose corticosteroids (LDS; intravenous hydrocortisone equivalent to presurgical oral dosing, fo

129 day; P = 0.01), and in lower total dosages (hydrocortisone equivalents, 1209 mg vs. 23 975 mg; P = 0

130 ges in the hippocampal volume during a brief hydrocortisone exposure and whether volumetric changes c

131 In nine (28%) of the 32 patients on hydrocortisone, fatigue scores reached a predefined cut-

132 ermia, helium, surfactant, glucose, insulin, hydrocortisone, fluid resuscitation and fluid removal, s

133 o receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering unti

134 In patients receiving hydrocortisone for septic shock, early initiation of tre

135 lacebo group 167 +/- 286; triiodothyronine + hydrocortisone group 466 +/- 495; p = 0.20).

136 (93%; 46% female) were evaluated (194 in the hydrocortisone group and 185 in the placebo group) at a

137 ccurred in 36 of 170 patients (21.2%) in the hydrocortisone group and 39 of 170 patients (22.9%) in t

138 oth in the entire group and the suramin plus hydrocortisone group at all three landmarks in both univ

139 rface area with hair loss, compared with the hydrocortisone group at all time points except at 6 week

140 ma vasopressin levels were not higher in the hydrocortisone group compared with the placebo group (64

141 The hydrocortisone group had a significantly higher survival

142 The hydrocortisone group required a shorter duration of vaso

143 ere neurodevelopmental impairment (7% in the hydrocortisone group vs 11% in the placebo group) was no

144 ld neurodevelopmental impairment (20% in the hydrocortisone group vs 18% in the placebo group), or wi

145 ut neurodevelopmental impairment (73% in the hydrocortisone group vs 70% in the placebo group), with

146 cantly different between groups (91.7 in the hydrocortisone group vs 91.4 in the placebo group; betwe

147 therapy (3.1 d; 95% CI, 1.1-5.1; shorter in hydrocortisone group) and required a lower total dose of

148 d DGE (29% vs 44%) tended to be lower in the hydrocortisone group.

149 s, n = 46) and those with late initiation of hydrocortisone (> 9 hr after vasopressors, n = 124).

150 In contrast, hydrocortisone had no effect on metabolic parameters.

151 Of 48 patients who completed both courses, hydrocortisone had no significant effect on outcome; how

152 Epinephrine and hydrocortisone have opposite effects on IL-8 production,

153 re collected after culture for 24-72 hr with hydrocortisone (HC) 1-5 microM, phorbol ester 20 ng/ml (

154 olunteers at baseline, and after intravenous hydrocortisone (HC) administered at moderate (250 mg) an

155 oid fibroblasts, and the altered response to hydrocortisone (HC) and differential regulation of a sub

156 Elimination of hydrocortisone (HC) from EN2 reduced the mean neurites p

157 (to inhibit adrenal cortisol secretion) + /- hydrocortisone (HC) in a randomised crossover design to

158 We have shown previously that hydrocortisone (HC) induces IgE synthesis in IL-4-stimul

159 KEY POINTS: Hydrocortisone (HC) is required for activation of large-

160 he present study we investigated the role of hydrocortisone (HC) on uridine-5'-triphosphate (UTP)-sti

161 onal therapy with aminoglutethimide (AG) and hydrocortisone (HC) plus megestrol acetate (MA) improved

162 own in standard culture medium or induced by hydrocortisone (HC).

163 Lipolysis was not stimulated by HG or high hydrocortisone (HC: 500 nM hydrocortisone) and was lower

164 e administered exogenous synthetic cortisol (hydrocortisone, HCT) using two different dosing regimens

165 The potency of 3 was similar to that of hydrocortisone (IC(50) = 0.01 microM), although 3 does n

166 Trials of galantamine, hydrocortisone, IgG, valganciclovir, isoprinosine, fluox

167 dritic cell by natural killer cells and that hydrocortisone improves outcome by limiting this immunos

168 quence furnished 1 in 11% overall yield from hydrocortisone in 15 linear steps.

169 Hydrocortisone in a dose of 200 mg/day in four divided d

170 l pressure (1C); avoiding use of intravenous hydrocortisone in adult septic shock patients if adequat

171 ined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neu

172 sessment of the neurodevelopmental safety of hydrocortisone in extremely preterm infants.

173 ner following stimulation with prolactin and hydrocortisone in HC11 cells expressing human PR-B.

174 /m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progres

175 The efficacy of hydrocortisone in patients with severe sepsis without sh

176 ethylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with

177 udy was to identify prescribing triggers for hydrocortisone in septic shock.

178 A randomized trial of stress-dose hydrocortisone in TBI patients with AI is underway.

179 on and after the administration of 100 mg of hydrocortisone in the patients (P</=0.03 for both compar

180 These findings do not support the use of hydrocortisone in these patients.

181 Treatment of primary TE monolayers with hydrocortisone in vitro induced expression of involucrin

182 counteracted the immunosuppressive effect of hydrocortisone in vivo.

183 nistering triiodothyronine, with and without hydrocortisone, in a model of septic shock.

184 nfusion of triiodothyronine, with or without hydrocortisone, in an ovine model of septic shock did no

185 by competition with exogenous bile acids and hydrocortisone, in contrast to progesterone, which produ

186 10(-7) M and 10(-8) M hydrocortisone increased NHE3 activity, and in their pre

187 The highest dose of hydrocortisone increased plasma BCAs in both insulin gro

188 Treatment of thymic organ cultures with hydrocortisone induced both medullary and subcapsular co

189 uce the amount of B-CLL cell death caused by hydrocortisone-induced apoptosis.

190 radioactive xenon washout technique after a hydrocortisone infusion (2 mg/kg per min for 16 h) or sa

191 Acute hydrocortisone infusion is associated with a rapid and r

192 n = 33) or high-dose (0.45 mg/kg IV; n = 33) hydrocortisone infusion.

193 in nondiabetic human subjects: 1) antecedent hydrocortisone infusions (simulating physiologic cortiso

194 iological concentrations of testosterone and hydrocortisone inhibited CatSper activation by progester

195 Stimulation with both prolactin and hydrocortisone is required for the induction of these lo

196 es as tracers; plasma clearance of 100 mg of hydrocortisone; levels of urinary cortisol metabolites;

197 of specific conditions, we suggest using IV hydrocortisone < 400 mg/day for >/= 3 days at full dose

198 divided into those with early initiation of hydrocortisone (< 9 hr after vasopressors, n = 46) and t

199 demonstrate an advantage of mitoxantrone and hydrocortisone (M+H) over hydrocortisone alone with resp

200 d immunosuppression, we investigated whether hydrocortisone modulates the dendritic cell/natural kill

201 in and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepinephrine and placebo

202 vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 1

203 ents were randomized to receive suramin plus hydrocortisone (n = 229) or placebo plus hydrocortisone

204 lus hydrocortisone (n = 229) or placebo plus hydrocortisone (n = 231).

205 1072 neonates screened, 523 were assigned to hydrocortisone (n = 256) or placebo (n = 267) and 406 su

206 either cortisol (single oral dose of 100 mg hydrocortisone, N = 34) or testosterone (three doses of

207 In a second step, the effects of hydrocortisone on dendritic cell/natural killer cell cro

208 To determine the effect of epinephrine and hydrocortisone on lipopolysaccharide (LPS)-induced inter

209 Although the pharmacodynamic effect of hydrocortisone on PMNLs and MNCs was similar, the peak i

210 ystemic vascular resistance (2C); and use of hydrocortisone only in children with suspected or proven

211 be activated by treatment of the cells with hydrocortisone or 5-iodo-2'-deoxyuridine.

212 from M. dunni cells by exposing the cells to hydrocortisone or 5-iodo-2'-deoxyuridine.

213 Specifically, GR agonists hydrocortisone or dexamethasone inhibited p53-dependent

214 tive GC dose was 100 mg (range, 50-267 mg of hydrocortisone or hydrocortisone equivalent for dexameth

215 fter surgery was 485 mg (range, 50-890 mg of hydrocortisone or hydrocortisone equivalent for predniso

216 nts were randomly assigned to receive either hydrocortisone or placebo in a circadian rhythm (10 mg/m

217 8 and 30 years of age received either 100 mg hydrocortisone or placebo on separate occasions approxim

218 ome devaluation (and thus habitual), whereas hydrocortisone or yohimbine alone have no such effect.

219 ake inhibitor reboxetine (RBX), (3) 30 mg of hydrocortisone, or (4) both drugs in combination.

220 re quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus dexamethasone) or

221 The addition of adrenaline, noradrenaline, hydrocortisone, or dexamethasone to lipopolysaccharide-a

222 intravenously 1 mg/kg of ovine CRH, 15 mg of hydrocortisone, or saline under double-blind conditions

223 riiodothyronine + placebo group 501 +/- 370; hydrocortisone + placebo group 167 +/- 286; triiodothyro

224 + placebo, 2) triiodothyronine + placebo, 3) hydrocortisone + placebo, or 4) triiodothyronine + hydro

225 were measured at 6-12 and 24-36 hours after hydrocortisone/placebo administration.

226 eive in total 8 doses of randomization-based hydrocortisone/placebo every 8 hours.

227 ized trial, investigated whether intravenous hydrocortisone premedication can reduce ATI.

228 Intravenous hydrocortisone premedication significantly reduces ATI l

229 interaction between HC and insulin was that hydrocortisone produced an elevation in levels of BCAs a

230 of 35 placebo recipients vs 20 (66.7%) of 30 hydrocortisone recipients (P =.31).

231 Hydrocortisone recipients had a greater improvement in m

232 rapies in the prevention of PTSD or ASD, but hydrocortisone reduced the risk of developing PTSD.

233 ant, sleep-related difficulties, addition of hydrocortisone reduced total sleeping problems and disor

234 ents with chronic fatigue syndrome, low-dose hydrocortisone reduces fatigue levels in the short term.

235 Hydrocortisone reduces the rate of pneumonia in patients

236 Immunosuppression of the frogs with hydrocortisone results in an acute, fulminant, lethal di

237 In primary hepatocytes, rhIL-6 and hydrocortisone separately increased plasminogen mRNA exp

238 hormones estradiol and progesterone, whereas hydrocortisone served as a substrate of only AcrAB-TolC.

239 t treatment exists in the form of thyroxine, hydrocortisone, sex steroids, growth hormone, and desmop

240 propose that 11betaHSD2-sensitive GCs (e.g., hydrocortisone) should be used in preference to dexameth

241 Hydrocortisone showed a large effect in reducing the ris

242 unological category, both immunoglobulin and hydrocortisone showed some limited effects but, overall,

243 However, hydrocortisone significantly increased GM1/lipid raft as

244 with IT triples (ITT) (MTX, cytarabine, and hydrocortisone sodium succinate [HSS]) as presymptomatic

245 Results showed that hydrocortisone spared the pulmonary neutrophilia but res

246 Hydrocortisone spared vasopressin requirements, reduced

247 ctional groups attached to the D-ring of the hydrocortisone steroid molecule produces compounds with

248 nt psychosocial adverse effects, addition of hydrocortisone substantially reduced their Strength and

249 nt study examined the effect of two doses of hydrocortisone (synthetic cortisol) administration on au

250 thiobenzothiazole-containing derivatives of hydrocortisone (termed MS4 and MS6) were examined using

251 Under moderate-dose hydrocortisone the autobiographical memory performance d

252 Healthy participants were administered hydrocortisone, the alpha2-adrenoceptor antagonist yohim

253 To assess whether early hydrocortisone therapy in extremely preterm infants is a

254 Objective: To determine whether hydrocortisone therapy in patients with severe sepsis pr

255 Importance: Adjunctive hydrocortisone therapy is suggested by the Surviving Sep

256 e syndrome led us to postulate that low-dose hydrocortisone therapy may be an effective treatment.

257 suppressed further by increasing the dose of hydrocortisone to 8 microg/kg/min, although the mean pea

258 ts suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the

259 ary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bronchopulmon

260 rs, with 1,000 units of heparin and 20 mg of hydrocortisone to reduce the incidence of thrombosis and

261 he Surviving Sepsis Campaign suggests giving hydrocortisone to septic patients only if their "blood p

262 n-1 was applied topically daily on wounds of hydrocortisone-treated or untreated animals.

263 rial, ATI levels were lower at week 16 among hydrocortisone-treated patients (1.6 vs. 3.4 microg/mL,

264 1.6 vs. 3.4 microg/mL, P = 0.02), and 26% of hydrocortisone-treated patients developed ATI compared w

265 associated with the wound healing defect in hydrocortisone-treated wounds, the enhanced expression o

266 nfected chronic granulomatous disease (CGD), hydrocortisone-treated, and neutropenic mice.

267 ffects were reported by three patients after hydrocortisone treatment and by one patient after placeb

268 ccelerated healing of wounds with or without hydrocortisone treatment as revealed by a reduction in t

269 Hydrocortisone treatment did not alter trypsinogen relea

270 rtisol breakdown affects the optimum dose of hydrocortisone treatment during critical illness.

271 Early low-dose hydrocortisone treatment has been reported to improve su

272 Hydrocortisone treatment reduced this suppressive functi

273 Although hydrocortisone treatment was associated with some improv

274 The degree of disability was reduced with hydrocortisone treatment, but not with placebo.

275 erall PPDC can be significantly reduced with hydrocortisone treatment.

276 ac arrest to discharge, stratified by use of hydrocortisone, using a Japanese health-insurance claims

277 accomplished from the commercially available hydrocortisone utilizing Hg(II)-catalyzed spiroketalizat

278 multicenter randomized trial of suramin plus hydrocortisone versus hydrocortisone alone.

279 rospective, randomized trial of suramin plus hydrocortisone versus placebo plus hydrocortisone, a pos

280 a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone.

281 In the hydrocortisone vs placebo groups, 21.5% vs 16.9% had sec

282 he setting of pneumovirus infection in vivo, hydrocortisone was administered to mice infected with pn

283 However, hydrocortisone was associated with a significant 1.69% r

284 s with adrenal insufficiency, treatment with hydrocortisone was associated with a significant reducti

285 ision to treat patients with stress doses of hydrocortisone was at the discretion of the treating int

286 Intra-venous hydrocortisone was given, however, his recovery was not

287 In addition, the administration of hydrocortisone was independent predictor of survival to

288 of extremely preterm infants, early low-dose hydrocortisone was not associated with a statistically s

289 erleukin-10 level in natural killer cells by hydrocortisone was partially dependent on the up-regulat

290 re already receiving two vasopressors before hydrocortisone was prescribed.

291 hock in whom vasopressors were initiated and hydrocortisone was prescribed.

292 In addition, hydrocortisone was used as a potent intestinal trophic f

293 assette and its up-regulation by insulin and hydrocortisone was verified by in vitro transfection.

294 with septic shock treated with low doses of hydrocortisone were enrolled.

295 adverse symptoms reported by patients taking hydrocortisone were mild, suppression of adrenal glucoco

296 stimulated cells with or without addition of hydrocortisone) were analyzed for the expression of gluc

297 PVM-infected mice responded to hydrocortisone with enhanced viral replication and accel

298 as earlier among patients with initiation of hydrocortisone within 9 hours.

299 colitis and failed to respond to intravenous hydrocortisone within about 5 days.

300 triple IT drug (methotrexate, cytarabine and hydrocortisone) without CRT.